Dr. Bevan Tandon, MD
Director of Cancer Cytogenomics
Dr. Tandon currently serves as Director of Cancer CytoGenomics. Dr. Tandon holds subspecialty board certifications in both Molecular Genetic Pathology, and also Hematopathology. His general certifications are in anatomic and clinical pathology. Dr. Tandon’s training in hematopathology consisted of an intensive fellowship and clinical instructorship at the University of Pittsburgh School of Medicine under the guidance of Dr. Steven Swerdlow, and his training in molecular genetic pathology was conducted at Washington University in St. Louis School of Medicine. Dr. Tandon completed his general residency training at Northwestern University Feinberg School of Medicine. Dr. Tandon is an active member of the Society for Hematopathology, and the Association for Molecular Pathology.
Eric Antoniou, PhD
Assistant Director, Cancer Genomics
Dr. Antoniou earned his PhD from the University of Bordeaux, France. He was formerly the senior manager of Cold Spring Harbor Laboratory genome sequencing center. He also held management positions at Ginkgo Bioworks and The Jackson Laboratory. Prior to these positions, he was an Assistant Professor at the University of Missouri-Columbia. Dr. Antoniou has eighteen years of experience in genomics science, including nine years in next generation sequencing.
KAYLEE BARBER, M.S.
Senior Genetic Counselor
Kaylee Barber is a board certified and licensed Genetic Counselor with experience in both prenatal and cancer genetics. At BioReference, she provides clinical expertise in researching and interpreting NGS data. Prior to joining BioReference, Kaylee was a prenatal genetic counselor with New Jersey Perinatal Associates in Livingston New Jersey, and a cancer genetic counselor with the Juravinski Cancer Center in Hamilton Ontario. She is originally from Ontario, Canada where she earned her Bachelorâ€™s degree in Molecular Biology and Biotechnology. She also earned a Masterâ€™s degree in Genetic Counseling from Sarah Lawrence College in New York.
Willonie Mendonca, MS
Willonie Mendonca is a board certified and licensed genetic counselor who has contributed to the field of cancer genetics and molecular diagnostic laboratory science for a decade. Currently at GenPath Oncology, a division of BioReference Laboratories, Inc., she provides expertise in analyzing and interpreting Next-Generation Sequencing (NGS) data from tumor samples through our OnkoSight platform. In her prior role at GeneDx, a subsidiary of BioReference Laboratories, Inc., she was involved in launching NGS-based inherited cancer tests. She led training and education for several GeneDx products including inherited cancer, whole exome sequencing, cardiology and neurology panels. She has previously worked at Myriad Genetics Laboratories, Inc., and was faculty at the University of Utah Genetic Counseling Program. Willonie is a member of the National Society of Genetic Counselors (NSGC) and has served as Chair of the Industry and Health Information Technology Special Interest Groups. She has been a site visitor for genetic counseling training programs, through the Accreditation Council for Genetic Counseling and served on ad hoc committees at the American Board of Genetic Counseling, Inc.
Naho Harada, MS
Naho Harada is a board certified and licensed Genetic Counselor with experience in cancer genetics. At BioReference Laboratories, Inc., she writes OnkoSight NGS reports for the Cancer Genomics Department. Prior to joining BioReference, Naho was a cancer genetic counselor with the University of Florida. She is originally from Tokyo, Japan, and earned her Bachelor’s degree in Genetics and Physiology at the University of British Columbia in Vancouver, British Columbia. She also earned a Master’s degree in Genetic Counseling from the University of Arkansas for Medical Sciences in Little Rock, Arkansas.
- Clinical Targeted Next-Generation Sequencing Panel Testing in Non-Small Lung Cancer: Single Institution Experience at a High Scale National Reference Laboratory
- Extended Myeloid Mutation Profiling using NGS in Triple-Negative Myeloproliferative Neoplasms: Single Institution Experience at a High Volume National Reference Laboratory
- Assessing the Possibility of RUNX1, ETV6 and GATA2 Related Germline Predisposition in Myeloid Neoplasms in a Somatic Cancer Setting